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Beryllium metal was classiﬁed in Europe collectively with beryllium compounds, e.g. soluble
salts. Toxicological equivalence was assumed despite greatly differing physicochemical prop-
erties. Following introduction of the Registration, Evaluation, Authorization and Restriction
of Chemicals (REACH) regulation, beryllium metal was classiﬁed as individual substance
and more investigational efforts to appropriately characterize beryllium metal as a speciﬁc
substance apart from soluble beryllium compounds was required. A literature search on tox-
icity of beryllium metal was conducted, and the resulting literature compiled together with the
results of a recently performed study package into a comprehensive data set. Testing per-
formed under Organisation for Economic Co-Operation and Development guidelines and
Good Laboratory Practice concluded that beryllium metal was neither a skin irritant, an
eye irritant, a skin sensitizer nor evoked any clinical signs of acute oral toxicity; discrepancies
between the currentlegal classiﬁcation of beryllium metal in the EuropeanUnion (EU) and the
experimental results were identiﬁed. Furthermore, genotoxicity and carcinogenicity were dis-
cussed in the context of the literature data and the new experimental data. It was concluded
that beryllium metal is unlikely to be a classical nonthreshold mutagen. Effects on DNA repair
and morphological cell transformation were observed but need further investigation to eval-
uate their relevance in vivo. Animal carcinogenicity studies deliver evidence of carcinogenicity
in the rat; however, lung overload may be a species-speciﬁc confounding factor in the existing
studies, and studies in other species do not give convincing evidence of carcinogenicity. Epide-
miology has been intensively discussed over the last years and has the problem that the studies
base on the same US beryllium production population and do not distinguish between metal
and soluble compounds. It is noted that the correlation between beryllium exposure and car-
cinogenicity, even including the soluble compounds, remains under discussion in the scientiﬁc
community and active research is continuing.
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INTRODUCTION
Beryllium metal has physical properties that make
its use essential for certain operations, but beryllium
is known to cause adverse health effects in humans
upon inhalation. Furthermore, the carcinogenicity
of beryllium and its compounds is under scientiﬁc
discussion and has been the subject of numerous
reviews and evaluations. To assess the risk of
beryllium for human health and focus the scientiﬁc
efforts, it is necessary to understand the exposure
pattern of humans to beryllium.
Exposure
The general population is continuously exposed to
low levels of naturally occurring beryllium (for
example in coal, wood, foodstuffs, gemstones) via
ambient air, drinking water, and diet. Aside from
the naturally occurring sources, exposure of humans
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43to beryllium is limited to inhalation and dermal con-
tact during occupational processes. Most of the ex-
posures occur in the manufacturing operations
during production of beryllium metal and beryllium-
containing alloys.
It should be noted that the overall market volume
of beryllium is relatively small;  146 metric tons are
sold worldwide per year.
1. Soluble beryllium compounds are extremely rare
in commerce with only small laboratory quanti-
ties being occasionally used. Aside from these
deminimus quantities, exposure of humans to
the soluble species is restricted to the primary ex-
traction and concentration facilities, which is
limited to four producing locations worldwide.
2. Approximately20tonsperyearofpureberyllium
metalisusedinveryspeciﬁcapplications,suchas
X-ray windows, nuclear/fusion reactors, and
aerospace applications, and is not used in con-
sumer goods except for the small quantity
(grams) used to manufacture high end audio
speakers. The beryllium metal parts are typically
supplied by specialty manufacturers as articles
in solid form, i.e. machined parts ready for
assembly.
3. Alloys containing beryllium represent by far the
biggest percentage (75%) of the 120 ton per year
beryllium-containing material market (Jaskula,
2010). They are used in electronics, energy, auto-
motive, and aeronautic applications because of
their high strength, elasticity, electrical and ther-
mal conductivity, resistance to oxidation, and
high melting point. Parts containing these alloys
are typically sold in a ﬁnished or semiﬁnished
solid form requiring no further processing and
are used as internal small components in various
industrial and consumer products.
In the European Union (EU), Japan and the United
States of America (USA), effective workplace and
environmental control measures are in place to min-
imize exposures of workers and the general public
during production and recycling operations. Recent
studies on the downstream processing of alloys and
recycling facilities indicate airborne concentrations
well below 0.2 lgm
 3 [Kent et al., 2007; Brush-
Wellman Inc. (unpublished data)].
Takingtheadvancesmadeincontrollingexposures
toberylliuminproductionoperations,theformonthe
market (solid article) and the low solubility of metal-
licberylliuminaqueousmediaintoaccount,theenvi-
ronmental or human exposure potential outside the
processing facilities is considered to be very limited.
Current classiﬁcation
Insoluble beryllium metal has historically been
classiﬁed together with its salts and soluble com-
pounds in the EU in the appendix to Directive 67/
548/EEC due to lack of data on individual beryllium
compounds. Full read across from individual sub-
stances was applied, despite the great differences
in physicochemical properties of the individual sub-
stances (Table 1), which strongly inﬂuences sys-
temic bioavailability of the individual compounds
and thus have signiﬁcant effects on the toxicity.
According to the European Regulation on Regis-
tration, Evaluation, Authorization and Restriction
of Chemicals (REACH), classiﬁcation of beryllium
metal as an individual substance is required. The
current harmonized classiﬁcation in the new Com-
mission Regulation 1272/2008 for beryllium is
a translation of the harmonized classiﬁcation of
beryllium and its soluble compounds into the new
Globally Harmonized System-language, plus addi-
tion of the H411 for long-lasting toxicity toward
aquatic organisms (Table 2).
TOXICITY
Acute toxicity and local effects
Acute oral toxicity of beryllium metal has recently
been tested in rats, and results are reported in this is-
sue of Annals of Occupational Hygiene (Strupp,
2010). The dose that was lethal to 50% of the test an-
imals (LD50) was found to be .2000 mg kg
 1 body
weight. This result was not surprising as oral bio-
availability of beryllium is known to bevery low. Al-
though no direct toxicokinetic data exists to support
this for the metal itself, studies on soluble beryllium
salts give indirect evidence that oral bioavailability
from solutions is ,1% across different animal spe-
cies (Richmond et al., 1964; Furchner et al., 1973),
and oral bioavailability of particulate matter was
found to be even by orders of magnitude lower
Table 1. Physicochemical properties of beryllium
compounds
Compound Melting
point (C)
Solubility in water
(g per 100 g water)
Beryllium metal 1287
a ,0.00005
b
Beryllium chloride 415
a 71.5
a
Beryllium sulphate 1127
a 41.3
a
Beryllium oxide 2578
a ,0.00005
b
aFrom CRC Handbook of Chemistry and Physics,
89th edition, Taylor and Francis, Boca Raton, USA.
bFrom beryllium consortium owned data.
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classiﬁcation of beryllium metal for acute oral toxic-
ity according to Regulation (EC) No 1272/2008
is considered required. The risk phrase R25-‘Toxic
if swallowed’ currently assigned to beryllium and
its compounds is not considered to be suitable for
beryllium metal as an individual substance.
Acute inhalation toxicity tests in rats were not
conducted as part of this study program, even though
the available literature on inhalation toxicity of be-
ryllium metal indicates that acute short-term (4 h)
exposure to extensive levels might well be tolerated
by rats without leading to mortality (Haley et al.,
1990). Delayed toxic effects in rats after short (acute
to subacute) inhalation exposure have been reported
in the public literature (Haley et al., 1990; Nikula
et al., 1997a; Finch et al., 1998b). From a technical
perspective, the current labeling for acute inhalation
(T
þ, R26-‘Very toxic by inhalation’) might not be
correct but is considered by the industry to be appro-
priate for warnings to beryllium workers to prevent
inhalation of beryllium metal dusts, and conducting
animal tests is not considered ethically justiﬁed
when scientiﬁc and regulatory consensus exists that
inhalation exposures to airborne beryllium should
be well controlled.
Local skin and eye effects of beryllium metal have
been tested in rabbits (Strupp, 2010). No irritative or
corrosive actions towards the skin have been ob-
served at any observation time point. Ocular applica-
tions resulted in minimal initial chemosis (likely due
to reaction of the eye to the powder as a foreign
body) that was completely reversible within 24 h
and slight initial redness that decreased within 24 h
to minimal reactions and was fully reversible within
7days(Grade0).Thus,themeanover24,48,and72h
does not meet or exceed the Grade 2 for redness or
chemosis, and the observed effects are fully revers-
ible within 21 days. Based on these results, no eye
or skin irritation classiﬁcation of beryllium metal ac-
cording to Regulation (EC) No 1272/2008 is consid-
ered required. The risk phrases R36/38-‘Irritating
to Eyes and Skin’ currently assigned to beryllium
and its compounds are not considered to be suitable
for beryllium metal.
Unlike insoluble forms, soluble beryllium com-
pounds are known to have a risk of a dermal sensiti-
zation reaction. Data in the public literature (Curtis,
1951; Zissu et al., 1996) does not give a satisfactory
answer for the metal. The single human study (Cur-
tis, 1995) investigated beryllium metal powder and
beryllium in solid forms (discs) in a patch test on
13 patients who had a history of sensitization reac-
tions in a beryllium plant and 16 control persons
who had no history of beryllium exposure. None of
the subjects of the control group reacted to either
form of the metal by spontaneous reactions and none
of thepatients reacted to themetal discs. Threeof the
Table 2. Classiﬁcation of beryllium metal/beryllium and beryllium compounds
Harmonized classiﬁcation in the
Dangerous substance directive
(Annex I of Directive 67/548/EEC;
Index No 004-001-00-7)
Classiﬁcation, labeling, and
packaging regulation (Annex VI of
Regulation (EC) No 1272/2008;
Index No 004-001-007)
Classiﬁcation R-phrase Meaning H-phrase Meaning
R49 (Carc. Cat. 2) May cause cancer by
inhalation.
H350i (Carc. Cat 1B) May Cause cancer
(inhalation).
R26 Also very toxic by inhalation. H330 Fatal if inhaled.
R25–R48/23 Also toxic if swallowed.
Also toxic: danger of serious
damage to health by
prolonged exposure through
inhalation.
H301
H372
Toxic if swallowed
Causes damage to organs
throughprolongedorrepeated
exposure.
R36/37/38 Irritating to eyes, respiratory
system, and skin.
H319
H335
H315
Causes serious eye irritation.
May cause respiratory
irritation.
Causes skin irritation.
R43 May cause sensitization by
skin contact.
H411 Toxic to aquatic life with
long-lasting effects (only for
beryllium compounds, not for
beryllium).
Carc. Cat. 5 Carcinogen Category.
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powder, but the author determined that this reaction
was likely caused by the impurity of a soluble beryl-
lium ﬂuoride salt, which was present at 0.025–0.2%
in the metal powder. Beryllium metal production
processes were changed in the 1950s, resulting in
the elimination of salt impurities. In a guinea pig
study (Zissu et al., 1996), soluble beryllium sulphate
was used to induce sensitivity and beryllium-
containing alloys for challenge. As the quantitative
systemic availability of metal ions is an important
factor in the development of a sensitization reaction,
the study is not considered suitable for assessment of
the metal. To investigate the skin sensitizing poten-
tial of beryllium metal, a guinea pig maximization
test was conducted with induction and challenge us-
ing beryllium metal (Strupp, 2010). None of the test
animals elicited positive skin reactions at challenge.
Based on these results, no classiﬁcation of beryllium
metal according to Regulation (EC) No 1272/2008 is
considered required. The risk phrase R43-‘May
cause sensitization by skin contact’ currently as-
signed to beryllium and its compounds is not consid-
ered to be suitable for beryllium metal as an
individual substance.
Repeated dose toxicity
While some repeated dose studies with soluble
compounds exist, no repeated dose studies with be-
ryllium metal are available. The only studies that
partly match this study type are studies with an
initial acute or subacute inhalation exposure period
(often targeting at in initial lung burden) and an
extended follow-up period (Haley et al., 1990;
Finch et al., 1991a; Nikula et al., 1997; Finch
et al., 1998b).
Although no animal experimental data are avail-
able, it is clear from epidemiology studies that beryl-
lium is hazardous to human health when inhaled.
Inhalation of high doses of soluble compounds is
known to cause acute beryllium disease, which is
an inﬂammatory obstructive lung disease after high
short-term exposure (Eisenbud, 1955; Cummings
et al., 2009) typically not or very rarely observed
anymore due to application of modern worker safety
measures. Chronic beryllium disease (CBD) can oc-
cur after exposure to comparatively low doses of be-
ryllium but requires involvement of an immune
response and there is some evidence that it might
predominantly or even exclusively occur in sensi-
tized workers believed to have a genetic predisposi-
tion (Deubner et al., 2001). CBD is a granulomatous
lung disorder with clinical symptoms similar to sar-
coidosis, currently diagnosed by the parallel occur-
rence of noncaseating granulomas and a positive
beryllium lymphocyte proliferation test. It is clearly
the most important toxicological aspect of beryl-
lium, and thus, classiﬁcation for speciﬁc target organ
(respiratory system) toxicity at low inhalation doses
is considered appropriate for beryllium metal. As
classiﬁcation for this endpoint is considered appro-
priate, and excellent scientiﬁc reviews on CBD exist
(Samuel and Maier,2008;McCleskeyet al.,2009), it
is not further discussed here but reference is made to
the mentioned reviews.
Genotoxicity and carcinogenicity
Carcinogenesis has been intensively studied in an-
imals. Furthermore, cancer rates have been studied
in US beryllium production workers. ‘Beryllium
and its compounds’ are classiﬁed by International
Agency for Research on Cancer and the German
Senatskommission zur Pru ¨fung gesundheits-
scha ¨dlicher Arbeitsstoffe der Deutschen Forschung-
sgemeinschaft (MAK commission) as Class 1
carcinogens (‘known carcinogen to humans’). In
the European community, beryllium and its com-
pounds are classiﬁed as Class 2 carcinogens (‘known
animal carcinogens that are suspected to be human
carcinogens’). The key literature on which the EU
classiﬁcation was based could not be identiﬁed as
the documentation at the respective European au-
thorities is restricted to meeting minutes. As a result,
an extensive literature search was conducted to iden-
tify the key studies.
The following databases were screened for publi-
cations relating to beryllium-induced carcinogenic-
ity in 2007: PubMed, MedPilot, ToxNET, and
Toxline Special. A total of 1531 publications were
identiﬁed dealing directly with toxicity of beryllium
and its compounds, of which 38 addressed carcino-
genicity and 21 genotoxicity.
Genotoxicity. When discussing potential carcino-
genic properties of a substance, information about
genotoxicity is required as a basis for assessment,
especially with regard to potential threshold/
nonthreshold modes of action.
Genotoxicity of beryllium metal was never inves-
tigated, while genotoxicity of soluble beryllium
compounds has been intensively studied. The likely
reason for this is the low solubility of the metal in the
cell culture media used in the in vitro tests and the
nontrivial inhalation exposure necessary for ade-
quate in vivo genotoxicity tests. Results obtained
with soluble beryllium compounds led to surpris-
ingly inconsistent results between independent
46 C. Strupplaboratories. No clear picture on genotoxicity could
be achieved, mainly due to limited experimental de-
signs and reporting. Data on exposure-relevant
beryllium species as they are found in an occupa-
tional environment does not exist (Gordon and
Bowser, 2003).
To ﬁll this data gap, the typical genotoxicity test-
ing program in vitro as recommended during safety
evaluation of substances for ofﬁcial registration
and as recommended in the literature (Mu ¨ller
et al., 1999; Kirkland et al., 2005) was conducted.
Internationally Organisation for Economic Co-
Operation and Development validated in vitro geno-
toxicity test methods were used, and detailed results
are reported in this issue of Annals of Occupational
Hygiene (Strupp, 2010). Genotoxicity of beryllium
metal extractswas investigated by areverse mutation
assay in Salmonella typhimurium/Escherichia coli
(Ames test), a mammalian cell chromosome aberra-
tion test in human lymphocytes and a mammalian
cell gene mutation test at the hypoxanthine-guanine
phosphoribosyltransferase locus (HPRT test) in V79
cells. DNA repair synthesis (as a marker of DNA
damage) was addressed in an unscheduled DNA syn-
thesis (UDS) assay in rat primary hepatocytes. Fur-
thermore, morphological cell transformation was
addressed by a cell transformation test in Syrian
Hamster embryo cells (SHE assay) (LeBoef et al.,
1996) and potential effects on DNA repair enzymes
by a modiﬁcation of the UDS assay.
It is recognized that there are limitations in the
ability of the assay systems used to predict complex
or secondary mechanisms of genotoxicity (which is
true for all in vitro systems), but primary genotoxi-
cants can be identiﬁed, which is important informa-
tion for risk assessment. The beryllium ion may play
a key role in biological processes as relative cytotox-
icity increases when applying soluble beryllium
compounds instead of metallic beryllium or metallic
particles with smaller diameter (thereby increasing
the surface) (Finch et al., 1988, 1991). However,
toxicity occurs only at high concentrations (high
micromolar range) and is obviously not-as may be
postulated for a metal-mediated by reactive oxygen
species production with subsequent initiation of ap-
optosis (Lavastre et al., 2002). Testing the soluble
metal salts and applying full read across to beryllium
metal are considered oversimpliﬁed as the solubility
(and thus the local exposure of cells coming in con-
tact with the metal ion) is in vivo unlikely to be
greater than in vitro in the chosen experimental
setup. Totestbarelywater-solublematerialsforgeno-
toxicity in vitro is a difﬁcult task and has limitations.
When medical devices are tested, typically extracts
of the device are prepared in accordance with ISO
10993 and applied in the genotoxicity tests and not
a mixture of soluble salts of all ingredients in the de-
vices. While primary isolated epithelial cell might be
incubated with particulate matter as they are mor-
phologically adapted to contact with particulate ma-
terial, it is not recommendable to expose all cell
types used in genotoxicity testing to the physical
stress that the presence of particles will cause. In
metal toxicity, the ion is typically made responsible
for genotoxic actions. As a basic approximation, an
ion formation test was conducted with the intention
to compare the dissolution behavior of beryllium
metal and beryllium chloride (as a representative
of soluble beryllium compounds) under conditions
simulating inhaled beryllium metal in the human
lung [nonabrasive shaking for up to 28 days in the
dark under normal lung (pH 7.4) and lysosomal
(pH 4.5) conditions]. It is recognized that this assay
cannot reﬂect the complex in vivo situation of the
lung, but it can at least deﬁne upper borders of expo-
sure. The result of this investigation (Strupp, 2010)
was that beryllium chloride obviously dissolved im-
mediately up to the limit of solubility, which was  4
to 7% of the berylliumtheoretically available for dis-
solution (5mass of the beryllium part of the loaded
beryllium chloride) in the normal lung medium and
 90% in the lysosomal ﬂuid with the lower pH.
The amount of dissolved beryllium did not signiﬁ-
cantly increase over the test period of 28 days and
just varied slightly in the range of normal variation.
Beryllium metal behaved differently. In both ﬂuids,
the amount of dissolved beryllium increased over
time but stayed largely below the amounts dissolved
from the chloride (Fig. 1).
The data indicates that dissolution kinetics of the
soluble forms and the metal are largely different.
Although considerable amounts of beryllium (up to
 30%) can dissolve in the artiﬁcial lysosomal ﬂuids
within 28 days, the local concentration achieved in
the lung is still considered to be by orders of magni-
tude lower than from soluble compounds as ions are
mobile and likely to be distributed/excreted more
quickly than dissolution of the metal particles oc-
curs. Furthermore, there is indirect evidence from
the toxicology studies that unlimited dissolution in
the lysosomes (with low pH) does not take place:
most of the beryllium metal, once inhaled, remains
in the lung of the experimental animals for an ex-
tended period. Clearance halftimes have been re-
ported to be 180–260 days in rats (Finch et al.,
1990), so unlimited immediate dissolution in the ly-
sosomes clearly does not take place. Beryllium can
be recovered from the lungs of workers with CBD
Beryllium metal II. - Literature Review and Discussion 47at autopsy, often years after exposure ceased (Verma
et al., 2003). Based on the results obtained, it is con-
sidered more relevant to test the metal extracts in the
genotoxicity assays in vitro rather than using soluble
compounds.
With regards to gene mutation, published litera-
ture with soluble beryllium compounds revealed no
genotoxic potential when applying the standard
Ames test (Arlauskas et al., 1985; Ashby et al.,
1990; Kuroda et al., 1991) and a weakly positive re-
sponse when applying nonstandard assays (Zakour
and Glickman, 1984; Arlauskas et al., 1985). In con-
trast to these results obtained in bacteria, published
literature on soluble beryllium compounds demon-
strated a weak positive response in mammalian cells
(Hsie, 1978, 1979; Miyaki et al., 1979).
In a recent bacterial gene mutation (Ames) assay
recently performed with beryllium metal extracts,
no mutagenic potential was observed. The same is
true for a mammalian cell gene mutation (HPRT)
assay (Strupp, 2010).
With regard to cytogenicity, published literature
with soluble beryllium compounds did not, in gen-
eral, show a potential for cytogenetic effects (Brooks
et al., 1989; Ashby et al., 1990), while in one publi-
cation a strong increase in structural chromosome
aberrations was observed in human lymphocytes
after treatment with BeSO4 (Larramendy et al.,
1981). A potential for sister chromatid exchange
(which could not beveriﬁed for hardly soluble beryl-
lium compounds) was observed in one study
(Kuroda et al., 1991), while no potential for sister
chromatid exchanges was identiﬁed in another study
(Anderson, 1983). In vitro micronucleus testing
in SHE cells was positive for soluble compounds
(Fritzenschaf et al., 1993), while oral exposure to
beryllium sulphate did not increase the incidence
of micronucleated bone marrow cells in vivo (Ashby
et al., 1990). A chromosome aberration assay
conducted with beryllium metal extracts (Strupp,
2010) did not demonstrate a cytogenetic activity of
the metal extract.
Morphological cell transformation upon exposure
of cells to soluble beryllium compounds was re-
ported to occur (Kommitowski, 1973; DiPaolo and
Casto, 1979; Dunkel et al., 1981; Zhou et al.,
1999; Joseph et al., 2001; Keshava et al., 2001). This
was veriﬁed for beryllium metal by a SHE cell trans-
formation assay conducted with beryllium metal ex-
tracts (Strupp, 2010). This ﬁnding is indicative that
the concentration of beryllium ions dissolved in the
culture media was obviously high enough to trigger
effects in cell culture systems during in vitro testing
and thus was adequate in all tests conducted for this
publication. The beryllium ion may interfere with
cell growth or metabolic regulation, but further con-
clusions are difﬁcult due to the general character of
the assay and the relatively small database on refer-
ence substances with elucidated mode of action. It
should be noted that the SHE cell transformation as-
say has a high speciﬁcity in prediction of rodent car-
cinogenesis, but predictive power for distinguishing
rodent and human carcinogens is lower, which may
be a result of the rodent source of cells. In a system-
atic approach to correlate known rat and human car-
cinogens with the results of the SHE assay, high
concordance (89%) in case of known rodent carcino-
gens was found, while concordancewas lower (37%)
between SHE assay results and known human carci-
nogens (Mauthe et al., 2001). Thus, residual uncer-
tainty on the relevance for man remains, especially
in absence of classical genotoxicity ﬁndings.
DNA repair synthesis, as an indirect marker of
DNA damage, was investigated with berylliummetal
extracts in primary rat hepatocytes in an UDS assay.
No DNA repair synthesis (and thus no hints of pre-
ceding DNA damage) was observed upon beryllium
metal exposure (Strupp, 2010). A reduction of the
expression of messenger RNA (mRNA) coding for
DNA repair proteins was observed upon incubation
Fig. 1. Dissolution behaviour of beryllium metal and beryllium chloride in artiﬁcial biological ﬂuids.
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lium compound (Joseph et al., 2001) and was sus-
pected to be a relevant mechanism for potential
carcinogenicity of beryllium (Beyersmann and
Hartwig, 2008). To investigate if this effect on the
mRNA level translates into a ﬁnal functional
response of the cells and might be relevant for beryl-
liummetal,theUDSassaywasslightlymodiﬁed.The
DNA of rat primary hepatocytes was intentionally
damaged by incubation with 2-acetylaminoﬂuorene,
aknownDNAdamagingagent,andcoincubatedwith
beryllium metal extracts (Strupp, 2010). DNA repair
synthesis was reduced by coincubation with beryl-
lium metal extract. However, it should be noted that
this effect was only observed when the concurrent
damage of the DNAwas massive (.80% cells in re-
pair), while no effects was observed in cells with
lower damage to the DNA (Fig. 2).
Taken together, the investigations on mutagenicity
of beryllium metal lead to the following conclusion:
beryllium metal is no classical mutagen as no hints
for gene mutation or cytogenicity were observed.
The ﬁndings for the metal extracts are not in contrast
to what was found with soluble compounds: al-
though some older studies reported positive results
with soluble compounds, there was no strong and
conclusive evidence of a mutagenic or cytogenic ef-
fect of soluble beryllium compounds in a weight-of-
evidence approach.
Beryllium metal does not directly damage the
DNA of the cells. There is evidence that beryllium
metal can lead to morphological cell transformation
and inhibition of DNA repair synthesis. The rele-
vance of these ﬁndings for humans is difﬁcult to
evaluate as the assays are relatively new and ade-
quate in vivo genotoxicity tests to put the observed
events into a quantitative perspective (e.g. are they
observed at realistic exposures in vivo or a high-dose
artifact in vitro?) are not available. The effects ob-
served on DNA repair do not seem to be restricted
to beryllium, similar ﬁndings are reported for soluble
nickel compounds (Hartwig et al., 1994), and com-
petition with the Mg
2þ required for DNA repair
was postulated as a potential reason. One conclusion
that can be drawn from the data is that the mecha-
nism of genotoxicity, if relevant in vivo, is unlikely
to be a nonthreshold mechanism. A practical thresh-
old can be postulated for beryllium metal since both
direct DNA repair enzyme inhibition or DNA/
protein expression-mediated effects do deﬁnitely
require more than one molecule (or in this case
ion) to inhibit all DNA repair enzyme molecules or
to bind to enough promoter regions to trigger trans-
formation effects in a cell. The effects observed in
the SHE assay and the modiﬁed UDS assay indicate
that the concentrations in the extracts were high
enough to lead to biological effects, so despite of
the only moderate achieved concentrations of beryl-
lium ions in the extracts, the cells were exposed
sufﬁciently, and exposure is more realistic than when
testing soluble compounds. The conclusion is that
beryllium metal is obviously not a classical mutagen
and has no cytogenetic effects at realistic exposure
conditions. The ﬁndings on DNA repair and cell
transformation deserve attention and further
investigations on their relevance in vivo; however,
a nonthreshold genotoxic effect of beryllium metal
is unlikely.
Carcinogenicity. Animal studies: As mentioned
previously, an extensive literature search was con-
ducted and screened for beryllium metal as the sub-
stance of interest and inhalation as the relevant route
of exposure. Five studies addressing carcinogenicity
after lung exposure to beryllium metal were identi-
ﬁed (one of these being reported or discussed in
seven publications; see Table 3). One additional
study with beryllium metal was identiﬁed (Hueper,
1954) but not considered to add relevant information
for risk characterization under human exposure
Fig. 2. UDS in rat primary hepatocytes upon coincubation with 2-acetylaminoﬂuorene and beryllium metal.
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sure in this study (intramuscular or intrapleural in-
jection) and thus not included. No carcinogenicity
study with oral or dermal exposure to beryllium
metal was identiﬁed.
The studies were evaluated for quality and report-
ing by the system proposed by Klimisch et al.
(1997). None of the identiﬁed studies were con-
ducted under Good Laboratory Practice and of the
1531 studies screened, only one of the individual
studies was designed and reported in a way that
could be evaluated as ‘reliable with restrictions (2)’
according to the system proposed by Klimisch. An-
other study was published in smaller fragments in
the scientiﬁc literature in form of abstracts of oral
presentations or posters, experimental, and review
articles. Although the individual publications do
not report sufﬁcient details to allow evaluation of
the data quality, the overall information provided
in the publications provides enough details to con-
vince that the study was performed under well-
controlled conditions and that the results are reliable.
The other publications were ‘not assignable (4)’ un-
der the Klimisch system as methods and results were
only reported in abstract form without description of
any experimental details or tabulation of individual
data.
However, despite the overall low quality of report-
ing, application of a weight-of-evidence approach
leads to the conclusion that the rat shows a robust
carcinogenic response to inhaled beryllium metal
even after single exposure. Experimental attempts
were made in the study program to reproduce this ef-
fect in other species. No carcinogenic responses in
mice and guinea pigs could be demonstrated
(Schepers, 1961; Finch et al., 1995; Nikula et al.,
1995; Finch et al., 1998a,b) and only challenging
the situation by using a sensitive animal model
(p53 knockout mice or A/J mice with a massive lung
tumor background) led to a weak positive response
to inhaled beryllium metal.
Differences between rats and other rodent/
nonrodent species in response to inhalation exposure
to poorly soluble particulate substances have been
observed and extensively discussed. Especially,
the relevance of tumorsobservedin rats at conditions
overloading the lung’s clearance capacity for
human health risk assessment has been discussed
(Oberdo ¨rster, 1995a,b; ILSI Risk Science Institute
Workshop Participants, 2000; Pott and Roller,
2005; Sivulka, 2006; Greim and Ziegler-Skylakakis,
2007; Valberg et al., 2009). The particle deposition,
clearance, and retention patterns have been demon-
strated to be different in rats compared to other
species (Muhle et al., 1990; Goodman, 1995; Snipes,
1996; Mauderly, 1997; Nikula et al., 1997; Nikula
et al., 2001; Elder et al., 2005; Hext et al., 2005),
mainly due to airway geometry. Rats retain more
of the particles in the lumen of the alveolar ducts
and the alveoli and react at lower levels with
Table 3. Animal carcinogenicity studies with beryllium metal
Test animal, route of exposure Carcinogenic response
identiﬁed
Data quality (Klimisch 1–4) Reference
Rat
inhalation
yes 2 (Reporting of the study is
fragmented into several
publications. Although the
level of detail in the
individual publications is
clearly not sufﬁcient for an
overall judgment on data
quality, the combination of
information from all
publications is considered to
give sufﬁcient proof that the
study was adequately
conducted.
Finch et al. (1994a/b), Finch
et al. (1995
, 1996); Belinsky
et al. (1994); Nickel-Brady
et al. (1994); Nikula et al.
(1995); Belinsky et al. (1997)
Rat
intratracheal instillation
Yes 4 (Study with high mortality
and relatively low animal
numbers per time point).
Groth et al. (1980)
Rat
intratracheal instillation
Yes 4 (Too little experimental
details given to evaluate the
study).
Litvinov et al. (1983)
Mouse
inhalation
Sensitive mouse strains:
weakly, wild-type mice: no
2 (Well-documented
guideline comparable study).
Finch et al. (1995, 1996,
1998b)
Guinea pig
intratracheal instillation
No 4 (No details on experiment). Schepers (1961)
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more material in the interstitium and do not demon-
strate the strong reactions observed in rats at the
same dose (Nikula et al., 1997). The human dose
equivalent at which such particle-related effects
could occur is signiﬁcantly higher than that in rat
due to the anatomical and physiological differences
between rats and humans with regard to particle de-
position and retention patterns as well as breathings
rates. Monkey and human macrophages have two/
ﬁve times the volume of rat macrophages, respec-
tively (Krombach, 1997). Thus, rat macrophages
may be more sensitive to overload. In addition, dif-
ferences in location of particles or macrophage-con-
taining particles may partially account for the
tendency of rats to respond to poorly soluble par-
ticles.
Lung overload is likely to have been present in the
rat carcinogenicity studies on beryllium metal. The
carcinogenicity study was performed with lung bur-
dens of 33, 84, and 420 lg( Finch et al., 1994a,
1996). Greater than 50% mortality in the high-dose
group was observed within 3 weeks after exposure;
in a parallel study on lung pathology, chronic inﬂam-
mation of the rat lung was observed at 10–100 lg,
and late-occurring minimal ﬁbrosis at 1.8 lg( Finch
et al., 1996). Furthermore, signiﬁcantly reduced
clearance of a tracer particle was described at lung
burdens of  2 lg( Finch et al., 1991b). It should
be noted that the positive carcinogenicity study in
rats was announced to be repeated at lower doses
not overloading the lung (Finch et al., 1994a,
1996), but no results on neoplastic parameters were
published, while general toxicity ﬁndings on this
study repeat were published (Finch et al., 1994b,c,
1996).
The general predictivity of rodent carcinogenicity
testing for the human situation is not satisfactory.
Alternative methods are currently under evaluation
but have not been validated or accepted as standard
methods. Systematic review of the carcinogenicity
potency database (Gold et al., 1998) revealed that
 50% of the chemicals tested for carcinogenicity
in rodents gave positive results in at least one spe-
cies. Compared to the data obtained by epidemiol-
ogy and occupational health monitoring, there is
a clear indication that there is a high amount of
false-positive results. Alternative methods (e.g. car-
cinogenomics, in vitro methods) are currently being
evaluated (Vinken et al., 2008) and are promising to
show a better correlation to the human situation than
the rodent carcinogenicity testing, but until the vali-
dations are ﬁnished, it remains unclear which tests
give better predictions for the human situation. Data
from alternative methods may add valuable informa-
tion to the available database, especially for the chal-
lenging human health risk assessment for inhalation
exposure to poorly soluble particles.
Epidemiology: Several epidemiological studies
on lung cancer risk in beryllium workers have been
performed. The early epidemiological work had
shortcomings in exposure reporting and confounding
factors were not adequately addressed (Mancuso and
El Attar, 1969; Mancuso et al., 1970, Mancuso,
1979, 1980; Infante et al., 1980; Wagoner et al.,
1980; Steenland and Ward, 1991). They were re-
cently reviewed in detail (Hollins et al., 2009).
Three more recent studies, performed according to
modern methods, are available: a larger cohort mor-
tality study (Wardet al.,1992),anested case–control
study basing on the same cohort in USA (Sanderson
et al., 2001) and a small mortality study based on the
Beryllium Case Registry in UK (Williams, 1996).
The difﬁculty in interpreting epidemiological data
with regard to beryllium metal is that the large co-
hort mortality study does not distinguish between
workers exposure to the metal or soluble com-
pounds. Referring to the description on exposure
given in the introduction of this article, exposure to
soluble beryllium compounds is restricted to the ex-
traction facilities, while exposure of downstream in-
dustry workers is toward the metal (mainly in
alloys), and general public is more or less only ex-
posed to the naturally occurring background levels.
The only study that deals with exposure to the
metal only, although not explicitly stated in the
study, is the Beryllium Case Registry study in UK
(Williams, 1996). It can be concluded that exposure
in this study was to the metal only as during the pe-
riod reported in the study no soluble beryllium com-
pounds were in commerce in UK. The study is based
on autopsy of all beryllium-exposed workers who
died from CBD (30 cases). No case of lung cancer
was identiﬁed among those deaths.
The large cohort study dealing with exposure to
metal and soluble compounds is the culmination of
a series of overlapping cohort mortality studies of
lung cancer in beryllium workers, funded, and per-
formed by the US National Institute for Occupa-
tional Safety and Health (NIOSH) in cooperation
with the US beryllium industry. It is the most com-
prehensive cohort mortality study to date, investigat-
ing 9332 workers at eight facilities (Ward et al.,
1992). The study recommended the performance of
a nested control study of the relationship of esti-
mated beryllium exposure to lung cancer, which
was subsequently carried out and published in
2001 (Sanderson et al., 2001).
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the overall standardized mortality ratio (SMR) was
1.26 (95% conﬁdence limits 1.12–1.42) which when
corrected for smoking was 1.09 (95% conﬁdence
limits include 1.0). Two of the eight study cohorts
had signiﬁcantly elevated lung cancer SMRs (1.69
and 1.24, respectively). One of these was reduced
to 1.49 after correction for smoking, the others cor-
rected to 1.09, 0.96, or 1.02 (95% conﬁdence limits
overlapping unity), depending on the smoking cor-
rection method and reference used (Ward et al.,
1992; Levy et al., 2002). Despite the paucity of sta-
tistically signiﬁcant elevated SMRs after correction
for smoking, the study presented a series of analyses
and ad hoc observations on the smoking uncorrected
SMRs. No analyses or ad hoc comparisons were per-
formed on smoking corrected SMRs. The single
plant where statistically signiﬁcant evidence was
identiﬁed led the authors to conclude that ‘Occupa-
tional exposure to beryllium is the most plausible ex-
planation for the increased risk of lung cancer
observed in this study’. Another study (Levy et al.,
2009) reanalyzed the data of the cohort mortality
study using proportional hazards analysis and reex-
amined patterns without conditioning on statistical
signiﬁcance. This study concluded ‘The patterns
observed provide little support for an association
of lung cancer with beryllium work factors. This re-
sult is likely due to the absence in the original
study of a signiﬁcant overall excess of lung cancer
after smoking adjustment’. The available historical
smoking information is a signiﬁcant limitation
and a source of scientiﬁc discussion (Richardson,
2010).
The nested control study (Sanderson et al., 2001)
performed as follow-up to the previously discussed
study used the largest single plant cohort (N 5
3569) in the cohort mortality study. With follow-up
through 1992, 142 subjects were identiﬁed who died
from lung cancer and these were compared to 710
control subjects, ﬁve selected for each case (for time
worked, cumulative, average, and maximum expo-
sure). Cases did not have signiﬁcantly higher values
for any of the exposure metrics until exposure was
lagged with latency assumptions of 10 and 20 years,
resulting in signiﬁcant case–control differences be-
ing observed. The study was criticized with the argu-
ment that cases and controls had different mean ages
of hire and that the lagging results were severely at-
tenuated when these differences were narrowed by
closer case–control matching on age at hire (Levy
et al., 2007). Also, in simulations in which cohort
members wereselected at randomto serveas ‘cases’,
large differences between these randomly selected
subjects and their controls were observed when
exposure was lagged (Deubner et al., 2007).
In response to these criticisms, the study data were
reanalyzed (Schubauer-Berigan et al., 2008) using
date of birth or age at hire as covariates, with the re-
sult that the relationship of lagged exposure to lung
cancer was attenuated. Most importantly in this rean-
alysis, neither time worked with beryllium nor cu-
mulative beryllium exposure were signiﬁcantly
associated with lung cancer whether lagged or un-
lagged, agreeing with Levy et al. (2007). This ana-
lysis showed that while average and maximum
exposure were not signiﬁcantly associated with lung
cancer unlagged or lagged 20 years, an association
persisted at lag 10 years.
There has been extensive commentary (Deubner
and Roth, 2009; Hein et al., 2009; Langholz and
Richardson, 2009; Wacholder, 2009) on the two
studies and their reanalysis. This commentary has
suggested that the results in Levy et al. (2007) may
be affected by negative bias due to the method of
control selection and that residual date of birth con-
founding may be present in the results in Schubauer-
Berigan et al. (2008).
Thus, considerable uncertainty remains whether
ratesoflungcanceraresigniﬁcantlyincreasedinberyl-
liumworkersaftersmokingcorrectionandwhetherthe
degree of beryllium exposure in beryllium workers
(exposure to different species of beryllium) is related
to the development of lung cancer. This uncertainty
was recently articulated in a review (Hollins et al.,
2009) and also in the EU Commission manuscript
‘Information Notices on occupational Diseases: A
guide to Diagnosis’ (European Commission, 2009).
Taken together, the epidemiological studies
deliver no clear evidence of whether acorrelation ex-
ists or not between beryllium (and compounds) inha-
lation exposure and lung carcinogenicity. The same
cohort is extensively discussed in the scientiﬁc com-
munity, and—depending on the reviewer—statistical
signiﬁcance is found or not. No initiatives to collect
data to build up a new cohort (reﬂecting current ex-
posures and with detailed investigation of smoking
habits) have been taken so far.
CONCLUSIONS
Beryllium metal differs signiﬁcantly from beryl-
lium salts in regard to physicochemical properties
and dissolution kinetics in body ﬂuids; read across
of toxicological properties is not considered appro-
priate for all endpoints. The current classiﬁcation
of beryllium and its compounds is not considered
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stance as new studies do not conﬁrm the risks for
acute oral toxicity, skin and eye irritating effects as
well as skin-sensitizing effects assigned to beryllium
metal.
Beryllium metal was found not to be a classical
mutagen but to have in vitro effects on cell transfor-
mation and DNA repair synthesis. From the results
of the in vitro tests, it can be postulated that
beryllium metal is unlikely to exhibit nonthreshold
effects.
The animal carcinogenicity studies on beryllium
metal are very much focused on carcinogenicity in
the rat. Although there is an indication that the rat
is not an ideal model for this endpoint for poorly
soluble particulate substances due to special lung
reactions, carcinogenicity data in other species are
scarce. It is concluded that additional carcinogenic-
ity studies in rats would not further elucidate the
situation, while mechanistic studies in nonrodent
species and evidence-based medicine have the
potential to add valuable information for human
health risk assessment.
Discussions on appropriate analysis of the existing
epidemiological data are still ongoing, and the evi-
dence for carcinogenicity is weak compared to typi-
cal known human carcinogens, despite very high
exposure levels during the periods epidemiologically
analyzed. In addition, as exposure in the epidemio-
logical studies included mixed exposure to soluble
and insoluble beryllium compounds, it is question-
able if this evidence is appropriate for classiﬁcation
of the pure metal.
The studies on beryllium metal, coupled with the
analysis of the literature, suggest that full read
across from soluble beryllium compounds to pure
beryllium metal may not be appropriate and demon-
strates that care should be taken when attempting to
classify metals and metal compounds by applying
read across. Decisions regarding the toxicity of data
rich substances should be based on high-quality
studies. It is clear that the often maligned REACH
regulation does provide a unique opportunity for
toxicologists, authorities, and industry to truly
assess the quality of past data and the opportunity
to generate new high-quality data that can and
should be used to guide our future risk management
initiatives.
FUNDING
The experimental work and literature search
conducted at Harlan Laboratories Ltd. was funded
by the REACH Beryllium consortium. The inter-
pretation of the results was fully committed to the
author.
Acknowledgements—I would like to thank David Deubner for
the greatly appreciated input on epidemiology.
REFERENCES
Anderson O. (1983) Effects of coal combustion products and
metal compounds on sister chromatid exchange (SCE)
in a macrophagelike cell line. Environ Health Persp; 47:
239–53.
Arlauskas A, Baker RS, Bonin AM et al. (1985) Mutagenicity
of metal ions in bacteria. Env Res; 36: 379–88.
Ashby J, Ishidate M, Stoner GD et al. (1990) Studies on the
genotoxicity of beryllium sulphate in vitro and in vivo.
Mut Res; 240: 217–25.
Belinsky SA, Nikula KJ, Hahn FFet al. (1994) p53 Alterations
in lung tumors induced in F344/N rats. Carcinogenesis;
N302: p189.
Belinsky SA, Swafford DS, Finch GL et al. (1997) Alterations
in the K-ras and p53 genes in rat lung tumors. Environ
Health Perspect; 105 (Suppl. 4): 901–6.
Beyersmann D, Hartwig A. (2008) Carcinogenic metal com-
pounds: recent insight into molecular and cellular mecha-
nisms. Arch Toxicol; 82: 493–512.
Brooks AL, Grifﬁth WC, Johnson NFet al. (1989) The induc-
tion of chromosome damage in CHO cells by beryllium and
radiation given alone and in combination. Radiat Res; 120:
494–507.
Cummings KJ, Stefaniak AB, Virji MA et al. (2009) A recon-
sideration of acute beryllium disease. Environ Health
Perspect; 117: 1250–6.
Curtis GH. (1951) Cutaneous Hypersensitivity Due to Beryl-
lium; A Study of Thirteen Cases. AMA Arch Derm Syphilol;
64 (4): 470–82.
Deubner D, Kelsh M, Shum M et al. (2001) Beryllium sensiti-
zation, chronic beryllium disease, and exposures at a
beryllium mining and extraction facility. Appl Occup Envi-
ron Hyg; 1: 579–92.
Deubner DC, Roth HD. (2009) Progress in understanding the
relationship between beryllium exposure and lung cancer.
Epidemiology; 20: 341–4.
Deubner DC, Roth HD, Levy PS. (2007) Empirical evaluation
of complex study designs: occupational exposure and can-
cer. J Occup Environ Med; 49: 953–9.
DiPaolo JA, Casto BC. (1979) Quantitative studies of in vitro
morphological transformation of syrian hamster cells by in-
organic metal salts. Cancer Res; 39: 1008–13.
Dunkel VC, Pienta RJ, Sivak A et al. (1981) Comparative neo-
plastic transformation responses of BALB/3T3-cells, Syrian
hamster embryo cells, and Rauscher murine leukemia virus-
infected Fisher 344 rat embryo cells to chemical carcino-
gens. J Natl Cancer Inst; 6: 1303–12.
Eisenbud M. (1955) Health hazards from beryllium. In White
DW Jr, Burke JE, editors. The metal beryllium. Cleveland,
OH: American Society of Metals. pp. 1–20.
Elder A, Gelein R, Finkelstein JN et al. (2005) Effects of sub-
chronically inhaled carbon black in three species. I. Reten-
tion kinetics, lung infalmmation, and histopathology.
Toxicol Sci; 88: 614–29.
European Commission. (2009) Information notices on occupa-
tional diseases: a guide to diagnosis.
Beryllium metal II. - Literature Review and Discussion 53Finch GL, Brooks AL, Hoover MD et al. (1988) Inﬂuence of
physico-chemical properties of beryllium particles on
toxicity to cultured cells. In Vitro Toxicol; 2: 287–97.
Finch GL, Hahn FF, Grifﬁth WC et al. (1994a) F344 rat lung
carcinogenicity from inhaled beryllium (Be) metal.
Toxicologist; 14: 264.
Finch GL, Haley PJ, Hoover MD, Cuddihy RG. (1994c) Re-
sponses of Rat Lungs Following Inhalation of Beryylium
Metal Particles to Achieve Relatively Low Lung Burdens.
Ann Occup Hyp; 38 (Suppl. 1): 419–24.
Finch GL, Haley PJ, Hoover MD, Hoover MD, Carlton WW,
Rebar AH, Mewhinney JA, Cuddihy RG. (1991a) Reduced
lung clearance induced by low lung burdens of beryllium
metal in rats. Toxicologist; 11 (1).
FinchGL,HaleyPJ,HooverMDetal.(1990)Interactionsbetween
inhaled beryllium metal and plutonium dioxide in rats: effects
on lung clearance. In Proceedings of the 4th International Con-
ference on the Combined Effects in Environmental Factors.
Baltimore, MD; pp. 49–52. Sept 30-Oct.3, 1990.
Finch GL, Haley PJ, Hoover MD et al. (1994b) Responses of
rat lungs to low lung burdens of inhaled beryllium metal. In-
hal Toxicol; 6: 205–24.
Finch GL, Hoover MD, Hahn FFet al. (1996) Animal models
of beryllium-induced lung disease. Environ Health Perspect;
104 (Suppl. 5): 973–79.
Finch GL, Hoover MD, Nikula KJ et al. (1995) Comparative
pulmonary responses to inhaled beryllium metal in rats ver-
sus mice. The international toxicologist 20-P-11.
Finch GL, Lowther WT, Hoover MD et al. (1991b) Effects of
beryllium metal particles on the viability and function of
cultured rat alveolar macrophages. J Toxicol Environ
Health; 34: 103–14.
Finch GL, March TH, Hahn FFet al. (1998a) Carcinogenic re-
sponse of transgenic heterozygous p53 knockout mice to in-
haled
239PuO2 or metallic beryllium. Toxicol Pathol; 26:
484–91.
Finch GL, Nikula KJ, Hoover MD. (1998b) Dose-response re-
lationship between inhaled beryllium metal and lung toxic-
ity in C3H mice. Toxicol Sci; 42: 36–48.
Fritzenschaf H, Kohlpoth M, Rusche B et al. (1993) Testing of
known carcinogens and noncarcinogens in the Syrian ham-
ster embryo cell (SHE) micronucleus test in vitro; correla-
tions with in vivo micronucleus formation and cell
transformation. Mut Res; 319: 47–53.
Furchner JE, Richmond CR, London JE. (1973) Comparative
metabolism of radionuclides in mammals. 8. Retention of
beryllium in the mouse, rat, monkey and dog. Health Phys;
24: 293–300.
Gold LS, Slone TH, Ames BN. (1998) What do animal cancer
tests tell us about human cancer risk?: overview of analysis
of the carcinogenic potency database. Drug Metab Rev; 30:
359–404.
Goodman JI. (1995) An analysis of the national toxicology
program’s (NTP) technical report (NTP TP 421) on the tox-
icology and carcinogenesis studies of talc. Regul Toxicol
Pharmacol; 21: 244–49.
Gordon T, Bowser D. (2003) Beryllium: genotoxicity and car-
cinogenicity. Mut Res; 533: 99–105.
Greim H, Ziegler-Skylakakis K. (2007) Risk assessment of bi-
opersistent granular particles. Inhal Toxicol; 19 (Suppl. 1):
199–204.
Groth DH, Kommineni C, MacKay GR. (1980) Carcinogenicity
of beryllium hydroxide and alloys. Environ Res; 21: 63–84.
Haley PJ, Finch GL, Hoover MD et al. (1990) The acute
toxicity of inhaled beryllium metal in rats. Fundam Appl
Toxicol; 15: 767–88.
Hartwig A, Mullenders LHF, Schlepegrell R et al. (1994)
Nickel(II) interferes with the incision step in nucleotide
excision repair in mammalian cells. Cancer Res; 54:
4045.
Hein MY, Deddens JA, Schubauer-Berigan MK. (2009) Bias
from matching on age at death in nested case-control stud-
ies. Epidemiology; 20: 330–38.
Hext PM, Tomenson JA, Thompson P. (2005) Titanium diox-
ide: inhalation toxicology and epidemiology. Ann Occ
Hyg; 49: 461–472.
Hollins DM, McKinley MA, Williams C et al. (2009) Beryl-
lium and lung cancer: a weight of evidence evaluation of
the toxicological and epidemiological literature. Crit Rev
Toxicol; 39: 1–32.
Hsie AW. (1978) Quantitative mammalian cell genetic toxicol-
ogy. Environ Sci Res; 15: 291–315.
Hsie AW, Johnson NP, Couch DB et al. (1979) Quantitative
mammalian cell mutagenesis and a preliminary study of the
mutagenic potential of metallic compounds. In Kharash N,
editor. Trace metals in health and disease. New York: Raven;
pp. 55–69.
Hueper WC. (1954) Experimental studies in metal
carcinogenesis. IV. Tissue reactions in rats and rabbits
after parenteral introduction of suspensions of arsenic, be-
ryllium, or asbestos in lanolin. J Natl Cancer Inst; 15:
113–29.
ILSI Risk Science Institute Workshop Participants. (2000) The
relevance of the rat lung response to particle overload for
human risk assessment: a workshop consensus report. Inhal
Toxicol; 12: 1–17.
Infante PF, WagonerJK, SprinceNL. (1980)Mortality patterns
from lung cancer and non-neoplastic respiratory disease
among white males in the beryllium case registry. Environ
Res; 21: 35–43.
Jaskula B. (2010) Beryllium. In U.S. geological survey, min-
eral commodity summaries. pp. 28–29.
JosephP, MuchnokT,OngT.(2001)Geneexpressionproﬁlein
BALB/c-3T3 cells transformed with beryllium sulphate.
Mol Carcinog; 32: 28–35.
Kent MS, Corbett ML, Glavin M. (2007) Characterization and
analysis of airborne metal exposures among workers recy-
cling cellular phones. In Proceedings of the 2007 IEEE
International Symposium on Electronics and the Environ-
ment, Orlando, USA, pp 112–16.
Keshava N, Zhou G, Spruill M et al. (2001) Carcinogenic
potential and genomic instability of beryllium sulphate in
BALB/c-3T3 cells. Mol Cell Biochem; 222: 69–76.
Kirkland D, Aardema M, Henderson L et al. (2005) Evaluation
of the ability of a battery of three in vitro genotoxicity tests
to discriminate rodent carcinogens and non-carcinogens. I.
Sensitivity, speciﬁcity and relative predictivity. Mutat Res;
584: 1–256.
Klimisch HJ, Andreae M, Tillmann U. (1997) A systematic ap-
proach for evaluating the quality of experimental toxicolog-
ical and ecotoxicological data. Regul Toxicol Pharmacol;
25: 1–5.
Kommitowski D. (1973) Die transformation von ﬁbroblasten
in vitro durch beryllium (Germ). Verh Dtsch Ges Path; 57:
421.
Krombach F, Mu ¨nzing S, Allmeling AM, Gerlach JT, Behr J,
Do ¨rger M. (1997) Cell Size of Alveolar Macrophages: An
Interspecies Comparison. Environ Health Perspect; 105
(Suppl 5): 1261–3.
Kuroda K, Endo G, Okamoto A et al. (1991) Genotoxicity of
beryllium, gallium and antimony in short-term assays. Mut
Res; 264: 163–70.
54 C. StruppLangholz B, Richardson D. (2009) Are nested case-controls
biased? Epidemiolgy; 20: 321–29.
Larramendy NC, Popescu NV, DiPaolo JA. (1981) Induction
by inorganic metal slats of sister chromatid exchanges and
chromosome aberrations in human and Syrian hamster cell
strains. Environ Mutagen; 3: 597–606.
Lavastre V, Roberge CJ, Pelletier M et al. (2002) Toxaphene,
but not beryllium, induces human neutrophil chemotaxis
and apoptosis via reactive oxygen species (ROS): involve-
ment of caspases and ROS in the degradation of cytoskeletal
proteins. Clin immunol; 104: 40–8.
Leboef RA, Kerckaert GA, Aardema MJ et al. (1996) The pH
6.7 Syrian hamster embryo cell transformation assay for as-
sessing the carcinogenic potential of chemicals. Mut Res;
356: 85–127.
LeFevre ME, Joel DD. (1986) Distribution of label after intra-
gastric administration of
7Be-labeled carbon to weanling
and aged mice. Proc Soc Exp Biol Med; 182: 112–19.
Levy PS, Roth HD, Deubner DC. (2007) Exposure to beryl-
lium and occurrence of lung cancer: a re-examination of
ﬁndings from a nested case-control study. J Occup Environ
Med; 49: 96–101.
LevyPS,RothHD,DeubnerDC.(2009)Exposuretoberyllium
and occurrence of lung cancer: ﬁndings from a cox propor-
tional hazards analysis of data from a retrospective cohort
mortality study. J Occup Environ Med; 51: 480–86.
Levy PS, Roth HD, Hwang PMT et al. (2002) Beryllium and
lung cancer: a reanalysis of a NIOSH cohort mortality study.
Inhal Toxicol; 14: 1003–15.
Litvinov NN, Kazenashev VF, Bugryshev PF. (1983) Blasto-
mogenic activities of various beryllium compounds (Russ).
Eksp Onkol; 5: 23–6.
Mancuso TF. (1970) Relation of Duration of Employment and
Prior Illness to Cancer Among Beryllium Workers. Environ
Res; 3 (3): 251–75.
Mancuso TF. (1979a) Occupational lung cancer among
beryllium workers.In LemenR and DementJ,editors.Dusts
and disease. Park Forest South, IL: Pathotox Publishers Inc.
pp. 463–82.
Mancuso TF. (1979b) Relation of duration of employment and
prior respiratory illness to respiratory cancer among beryl-
lium workers. Environ Res; 3: 251–75.
Mancuso TF. (1980) Mortality study of beryllium industry
workers’ occupational lung cancer. Environ Res; 21:
48–55.
MancusoTF, ElAttar AA.(1969)Epidemiologicalstudyofthe
beryllium industry: cohort methodology and mortality stud-
ies. J Occup Med; 11: 442–34.
Mauderly JL. (1997) Relevance of particle-induced rat lung
tumorsforassessinglungcarcinogenichazardandhumanlung
cancerrisk.EnvironHealthPerspect;105(Suppl.5):1337–46.
Mauthe RJ, Gibson DP, Bunch RT et al. (2001) The Syrian
hamster embryo (SHE) cell transformation assay: review
of the methods and results. Toxicol Pathol; 29: 138–46.
McCleskey TM, Buchner V, Field RW et al. (2009) Recent
advances in understanding the biomolecular basis of chronic
berylliumdisease:a review.RevEnvironHealth;24:75–115.
Miyaki M, Akamatsu N, Ono T et al. (1979) Mutagenicity of
metal cations in cultured cells from Chinese hamster. Mutat
Res; 68: 259–63.
Muhle H, Bellmann B, Creutzenberg O et al. (1990) Dust over-
loadingof lungs after exposure of rats to particlesof lowsol-
ubility: comparative studies. J Aerosol Sci; 21: 374–77.
Mu ¨ller L, Kikuchi Y, Probst G et al. (1999) ICH-harmonised
guidances on genotoxicity testing of pharmaceuticals: evo-
lution, reasoning and impact. Mut Res; 436: 195–225.
Nickel-Brady C, Hahn FF, Finch GL et al. (1994) Analysis of
K-ras, p53 and c-raf-1 mutations in beryllium-induced rat
lung tumors. Carcinogenesis; 15: 257–62.
Nikula KJ, Swafford DS, Hoover MD et al. (1997a) Chronic
granulomatous pneumonia and lymphocytic responses in-
duced by inhaled beryllium metal in A/J and C3H/HeJ mice.
Toxicol Pathol; 25: 2–212.
Nikula KJ, Finch GL, Hoover MD et al. (1995) Comparative
pulmonary carcinogenicity of beryllium in A/J and C3H/
HeJ mice. Toxicologist; 15: 47.
Nikula KJ, Avila KJ, Grifﬁth WC et al. (1997b) Lung tissue re-
sponses and site of particle retention differ between rats and
cynomolgus monkeys exposed chronically to diesel exhaust
and coal dust. Fundam Appl Toxicol; 37: 37–53.
Nikula KJ, Vallyathan V, Green FH, Hahn FF. (2001) Inﬂuence
of Concentration or Dose on the Distribution of Particulate
Material in Rat and Human Lungs. Environ Heath Perspect;
109 (4): 311–8.
Oberdo ¨rster G. (1995a) Lung particle overload: implications
for occupational exposures to particles. Regul Toxicol Phar-
macol; 27: 127–35.
Oberdo ¨rster G. (1995b) The NTP talc inhalation study: a criti-
cal appraisal focused on lung particle overload. Regul
Toxicol Pharmacol; 21: 233–41.
Pott F, Roller M. (2005) Carcinogenicity stud with ninteen
granular dusts in rats. Eur J Oncol; 10: 249–81.
Richardson DB. (2010) Occupational exposures and lung can-
cer: adjustment for unmeasured confounding by smoking.
Epidemiology; 21: 181–86.
Richmond CR, London JE, Drake GA et al. (1964) Whole-
body retention of orally and intravenously administered
beryllium-7 by beagles. LA Rep; 127: 66–75.
Samuel G, Maier LA. (2008) Immunology of chronic beryl-
lium disease. Curr Opin Allerg Clin Immunol; 8: 126–34.
Sanderson WT, Ward EM, Steenland K et al. (2001) Lung can-
cer case-control study of beryllium workers. Am J Ind Med;
39: 133–44.
Schepers GWH. (1961) Neoplasia experimentally induced
by beryllium compounds. Prog Exp Tumor Res; 2:
203–44.
Schubauer-Berigan MK, Deddens JA, Steenland K et al.
(2008) Adjustment for temporal confounders in a reanalysis
of a case-control study of beryllium and lung cancer. Occup
Environ Med; 65: 379–83.
Sivulka DJ. (2006) Comparison of non neoplastic respiratory
responses in animals after inhalation of water soluble and
insoluble metal compounds. White paper available from
NiPERA.
Snipes MB. (1996) Current information on lung overload in
non-rodent mammals: contrast with rats. Inhal Toxicol; 8
(Suppl): 91–109.
Steenland K, Ward E. (1991) Lung cancer incidence among
patients with beryllium disease: a cohort mortality study.
J Natl Cancer Inst; 83: 1380–5.
Strupp C. (2011) Beryllium Metal I. Experimental Results on
Acute Oral Toxicity, Local Skin and Eye Effects, and Gen-
otoxicity. Ann Occup Hyg; 55: 30–42.
Valberg PA, Bruch J, McCunney RJ. (2009) Are rat results
from intratracheal instillation of 19 granular dusts a reliable
basis for predicting cancer risk? Regul Toxicol Pharmacol;
54: 72.
Verma DK, Ritchie AG, Shaw ML. (2003) Measurementof
beryllium in lung tissue of a chronic beryllium disease case
and cases with sarcoidosis. Occup Med; 53: 223–7.
Vinken M, Doktorova T, Ellinger-Ziegelbauer H et al.( 2 0 0 8 )
The carcinoGENOMICS project: critical selection of
Beryllium metal II. - Literature Review and Discussion 55modelcompoundsforthedevelopmentofomics-basedinvitro
carcinogenicity screening assays. Mutat Res; 659: 202–10.
Wacholder S. (2009) Bias in full cohort and nested case-
control studies? Epidemiology; 20: 339–40.
Wagoner JK, Infante PF, Bayliss DL. (1980) Beryllium: an
etiological agent in the induction of lung cancer, non-
neoplastic respiratory disease and heart disease among
industrially exposed workers. Environ Res; 21: 15–34.
Ward E, Okun A, Ruder A et al. (1992) A mortality study of
workers at 7 beryllium processing plants. Am J Ind Med;
22: 885–904.
Williams WJ. (1996) United Kingdom beryllium registry:
mortality and autopsy study. Environ Health Perspect; 104
(Suppl. 5): 949–51.
Zakour RA, Glickman BW. (1984) Metal-induced mutagenesis
in the lacI gene of Escherichia coli. Mutat Res; 126: 9–18.
Zhou G, Hubbs AF, Batelli L et al. (1999) Cell transforming
potential of beryllium in cultured mammalian cells. Environ
Mol Mutagen; 33: 71.
Zissu D, Binet S, Cavelier C. (1996) Patch Testing with Beryl-
lium Alloy Samples in Guinea Pigs. Contact Dermatitis; 34
(3): 196–200.
56 C. Strupp